Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence

BJU International

Volumn 92, Issue 4, 2003, Pages 389-392

  Friedrich, M G ^a,c   Toma, M I ^a   Petri, S ^b   Huland, H ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; COX 2; Non muscle invasive bladder cancer; Recurrence

Indexed keywords

ANTIBODY; CD34 ANTIGEN; CYCLOOXYGENASE 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER CARCINOMA; CALCULATION; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL ISOLATION; CONTROLLED STUDY; DATA ANALYSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PRIORITY JOURNAL; STAINING; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TRANSURETHRAL RESECTION; UROGENITAL TRACT TUMOR; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICROCIRCULATION; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; URINARY BLADDER NEOPLASMS;

EID: 0041408871     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04345.x     Document Type: Article

References (34)

1. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Ann Rev Biochem 1986; 55: 69-102
2. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40
3. Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors. a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996; 25: 363-72
4. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999; 106: 37S-42S
5. Lim HY, Joo HJ, Choi JH et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 519-25
6. Yip-Schneider MT, Barnard DS, Billings SD et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 139-46
7. Mohammed SI, Knapp DW, Bostwick DG et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-50
8. Hixson L, Alberts D, Krutzsch M et al. Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994; 3: 433-8
9. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-4
10. Wolff H, Saukkonen K, Anttila S et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001
11. Tucker ON, Dannenberg AJ, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-90
12. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002; 55: 429-34
13. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in viva. J Urol 2000; 164: 820-5
14. Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73
15. Fox SB, Taylor M, Grondahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 2001; 195: 236-43
16. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Medical 1983; 172: 214-8.
17. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996; 86: 353-64
18. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley & Sons, 1997
19. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11
20. Marrogi AJ, Travis WD, Welsh JA et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 4739-44
21. Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002; 198: 435-41
22. Komhoff M, Guan Y, Shappell HW et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157: 29-35
23. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S. Expression of cyclooxygenase-2 in patients with bladder cancer. J Urol 2001; 165: 1468-72
24. Tanaka F, Otake Y, Yanagihara K et al. Evaluation of angiogenesis in non-small cell lung cancer. Cancer Clin Res 2001; 7: 3410-5
25. Kumar S, Ghellal A, Li C et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Res 1999; 59: 856-61
26. Kim YB, Kim GE, Cho NH et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002; 95: 531-9
27. Ferrandina G, Lauriola L, Zannoni GF et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002; 87: 1145-52
28. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-5
29. Ferrandina G, Lauriola L, Zannoni GF et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13: 1205-11
30. Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7: 861-7
31. Achiwa H, Yatabe Y, Hida T et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001-5
32. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002; 19: 527-34
33. Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002; 60: 816-21
34. Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumour invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188-93